Melanie Leveridge
GlaxoSmithKline (United Kingdom)(GB)Age UK(GB)
Publications by Year
Research Areas
Epigenetics and DNA Methylation, Mass Spectrometry Techniques and Applications, Histone Deacetylase Inhibitors Research, Metabolomics and Mass Spectrometry Studies, Protein Degradation and Inhibitors
Most-Cited Works
- → A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response(2012)940 cited
- → Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition(2015)231 cited
- → The Evolution of MALDI-TOF Mass Spectrometry toward Ultra-High-Throughput Screening: 1536-Well Format and Beyond(2015)140 cited
- → Advances in high‐throughput mass spectrometry in drug discovery(2022)118 cited
- → Enabling Lead Discovery for Histone Lysine Demethylases by High-Throughput RapidFire Mass Spectrometry(2011)99 cited
- → Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives(2016)67 cited
- → Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives(2016)59 cited
- → Demonstrating Enhanced Throughput of RapidFire Mass Spectrometry through Multiplexing Using the JmjD2d Demethylase as a Model System(2013)41 cited
- → A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease Using RapidFire Mass Spectrometry(2015)36 cited
- → A Systematic Investigation of the Best Buffers for Use in Screening by MALDI–Mass Spectrometry(2016)36 cited